A petition has been submitted to the National Assembly requesting a two-year delay in the implementation of cryptocurrency taxation from 2027 to 2029. The petitioner argued that a reduction in personal income tax could lead to a decrease in corporate tax, resulting in a loss of tax revenue. The petitioner, identified as Mr. Cho, submitted the "Petition for a Two-Year Delay in Cryptocurrency Taxation" on the 17th, which has garnered support from over 100 people and is currently under review for public disclosure. Mr. Cho stated that Dunamu paid 432.6 billion KRW in taxes last year, but the expected corporate tax for this year is projected to drop to 30 billion KRW. He explained that as taxation approaches, people are leaving the cryptocurrency market, causing a sharp decline in exchange revenues and corporate taxes. Furthermore, while an increase in tax revenue of 400 to 600 billion KRW is anticipated from digital asset taxation, there are concerns about a potential decrease of 200 billion KRW in tax revenue during a downturn. Currently, the government has announced that the tax will be implemented in January 2027, but the People Power Party is advocating for a delay due to insufficient infrastructure.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.



Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.












Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.